Lilly Backs Broad Diabetes Range to Challenge Rivals

Eli Lilly & Co. is betting on a “broad” range of diabetes products including pills, insulins and a once-a-week treatment to take on bigger competitors, said Enrique Conterno, president of Lilly Diabetes.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.